Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcrc.2013.08.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer.
Invest New Drugs
December 2024
Division of Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Antiangiogenic drugs may cause vascular normalization and correct hypoxia in tumors, shifting cells to mitochondrial respiration as the primary source of energy. In turn, the addition of an inhibitor of mitochondrial respiration to antiangiogenic therapy holds potential to induce synthetic lethality. This study evaluated the mitochondrial inhibitor ME-344 in combination with bevacizumab in patients with refractory metastatic colorectal cancer (mCRC).
View Article and Find Full Text PDFEfficacy and Safety of Mydriatic Microdrops for Retinopathy of Prematurity Screening: The MyMiROPS Randomized Clinical Trial.
JAMA Ophthalmol
December 2024
Second Department of Ophthalmology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece.
Importance: Commercial mydriatics administered in preterm infants during retinopathy of prematurity (ROP) screening have been associated with various cardiorespiratory and gastrointestinal adverse events.
Objective: To examine whether microdrops of a combined mixture of 1.67% phenylephrine and 0.
12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept.
Indian J Ophthalmol
January 2025
Department of Ophthalmology, American University of Beirut, Beirut, Lebanon.
Purpose: To investigate the 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration (nAMD) in eyes previously treated with aflibercept.
Methods: Retrospective chart review of patients with nAMD previously treated with aflibercept for at least 12 months and subsequently transitioned to ziv-aflibercept between January 1, 2019, and December 31, 2022, for a period of at least 12 months. Participants were identified, and their clinical and imaging information was extracted from our electronic health records system.
Predicting corneal decompensation in Fuchs endothelial corneal dystrophy with Scheimpflug tomography and clinical parameters.
Indian J Ophthalmol
January 2025
Department of Ophthalmology, Université Paris Cité, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Purpose: This study aims to evaluate the efficacy of various tomographic indices, both established and novel, in predicting endothelial decompensation leading to either spontaneous corneal transplantation or transplantation following cataract surgery in patients with Fuchs endothelial corneal dystrophy (FECD).
Methods: In this cross-sectional, retrospective study, we reviewed the files of 93 eyes from 54 FECD patients undergoing regular follow-up. We recorded clinical metrics such as morning visual disturbance (MVD) and corrected distance visual acuity.
The effect of educational intervention through sending emails on improving physical posture in female computer users of Eastern Iran: a quasi-experiment study.
Front Digit Health
December 2024
Cardiovascular Research Center, Health Policy and Promotion Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Background: Musculoskeletal disorders are among the most common occupational injuries and disabilities in developing and industrialized countries. This study aims to determine the effectiveness of e-mail training to improve the physical posture of female computer users at Birjand University of Medical Sciences in Iran.
Methods: The present interventional research explores the effect of email-based training to correct the body posture of female computer users in Birjand, Iran.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!